Hematology Section, Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
Hematology. 2023 Dec;28(1):2229115. doi: 10.1080/16078454.2023.2229115.
Sickle cell disease (SCD) is one of the most common hematological diseases, which results in variable complications. The treatment of SCD is evolving but limited options are available for now. Acute chest syndrome (ACS) is one of the serious complications observed in SCD and a challenging one in prevention. Crizanlizumab is a monoclonal antibody that binds to P-selectin and improves blood flow by preventing sickle cell adhesion to endothelium, resulting in improvement of vaso-oclusive crises (VOC). It is not well evaluated in terms of ACS prevention. Here we report a 23-year-old patient with SCD and recurrent ACS; she was started on Crizanlizumab and she had no more ACS, but once she was off Crizanlizumab she developed ACS again, later Crizanlizumab was re-started, and the patient has improved significantly.
镰状细胞病（SCD）是最常见的血液系统疾病之一，可导致多种并发症。SCD 的治疗方法在不断发展，但目前可供选择的方法有限。急性胸部综合征（ACS）是 SCD 观察到的严重并发症之一，预防具有挑战性。Crizanlizumab 是一种单克隆抗体，可与 P 选择素结合，通过防止镰状细胞与内皮细胞黏附来改善血流，从而改善血管阻塞危象（VOC）。其在预防 ACS 方面的评价并不完善。在此，我们报告了一名 23 岁的 SCD 合并复发性 ACS 患者；她开始使用 Crizanlizumab 治疗，此后未再发生 ACS，但一旦停药，ACS 再次发作，随后再次开始使用 Crizanlizumab 治疗，患者病情显著改善。
